At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
AZD2171 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating AZD2171, 5-fluorouracil, and 3 other interventions for Colorectal Cancer. Completed, enrolled 215 participants across 43 sites in 9 countries.
Detailed Summary
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesAustria, Belgium, Canada, Czechia, France, Germany, Italy, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionNov 2007
Study CompletionOct 2009
TodayJul 2026
First PostedJan 19, 2006
Enrollment StartJan 1, 2006
Primary CompletionNov 1, 2007
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.5 years ago
Interventions
AZD2171drug
oral tablet
5-fluorouracildrug
intravenous infusion
Leucovorindrug
intravenous infusion
Oxaliplatindrug
intravenous infusion
Bevacizumabdrug
intravenous infusion